Summary

Cardiac Troponin Market – Scope of Report
TMR’s report on the global cardiac troponin market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global cardiac troponin market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cardiac troponin market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cardiac troponin market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cardiac troponin market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cardiac troponin market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cardiac troponin market.

The report delves into the competitive landscape of the global cardiac troponin market. Key players operating in the global cardiac troponin market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cardiac troponin market profiled in this report.

Key Questions Answered in Global cardiac troponin Market Report
• What is the sales/revenue generated by cardiac troponin across all regions during the forecast period?
• What are the opportunities in the global cardiac troponin market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cardiac Troponin Market – Research Objectives and Research Approach
The comprehensive report on the global cardiac troponin market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cardiac troponin market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cardiac troponin market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiac Troponin Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiac Troponin Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Cardiac Troponin Market Analysis and Forecast, by Troponin Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Troponin Type, 2020-2034
6.3.1. Troponin I
6.3.2. Troponin T
6.3.3. Troponin C
6.4. Market Attractiveness, by Troponin Type
7. Global Cardiac Troponin Market Analysis and Forecast, by Setting
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Setting, 2020-2034
7.3.1. Laboratory Setting
7.3.2. Point-of-Care (POC) Testing
7.4. Market Attractiveness, by Setting
8. Global Cardiac Troponin Market Analysis and Forecast, by Indication
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2020-2034
8.3.1. Myocardial Infarction
8.3.2. Congestive Heart Failure
8.3.3. Acute Coronary Syndrome
8.3.4. Others (cardiomyopathy, etc.)
8.4. Market Attractiveness, by Indication
9. Global Cardiac Troponin Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals & Clinics
9.3.2. Diagnostic Laboratories
9.3.3. Homecare Settings
9.3.4. Others (Research Institutes, etc.)
9.4. Market Attractiveness, by End-user
10. Global Cardiac Troponin Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Cardiac Troponin Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Troponin Type, 2020-2034
11.2.1. Troponin I
11.2.2. Troponin T
11.2.3. Troponin C
11.3. Market Attractiveness, by Troponin Type
11.4. Market Value Forecast, by Setting, 2020-2034
11.4.1. Laboratory Setting
11.4.2. Point-of-Care (POC) Testing
11.5. Market Attractiveness, by Setting
11.6. Market Value Forecast, by Indication, 2020-2034
11.6.1. Myocardial Infarction
11.6.2. Congestive Heart Failure
11.6.3. Acute Coronary Syndrome
11.6.4. Others (cardiomyopathy, etc.)
11.7. Market Attractiveness, by Indication
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals & Clinics
11.8.2. Diagnostic Laboratories
11.8.3. Homecare Settings
11.8.4. Others (Research Institutes, etc.)
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Troponin Type
11.11.2. By Setting
11.11.3. By Indication
11.11.4. By End-user
11.11.5. By Country
12. Europe Cardiac Troponin Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Troponin Type, 2020-2034
12.2.1. Troponin I
12.2.2. Troponin T
12.2.3. Troponin C
12.3. Market Attractiveness, by Troponin Type
12.4. Market Value Forecast, by Setting, 2020-2034
12.4.1. Laboratory Setting
12.4.2. Point-of-Care (POC) Testing
12.5. Market Attractiveness, by Setting
12.6. Market Value Forecast, by Indication, 2020-2034
12.6.1. Myocardial Infarction
12.6.2. Congestive Heart Failure
12.6.3. Acute Coronary Syndrome
12.6.4. Others (cardiomyopathy, etc.)
12.7. Market Attractiveness, by Indication
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals & Clinics
12.8.2. Diagnostic Laboratories
12.8.3. Homecare Settings
12.8.4. Others (Research Institutes, etc.)
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Troponin Type
12.11.2. By Setting
12.11.3. By Indication
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Cardiac Troponin Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Troponin Type, 2020-2034
13.2.1. Troponin I
13.2.2. Troponin T
13.2.3. Troponin C
13.3. Market Attractiveness, by Troponin Type
13.4. Market Value Forecast, by Setting, 2020-2034
13.4.1. Laboratory Setting
13.4.2. Point-of-Care (POC) Testing
13.5. Market Attractiveness, by Setting
13.6. Market Value Forecast, by Indication, 2020-2034
13.6.1. Myocardial Infarction
13.6.2. Congestive Heart Failure
13.6.3. Acute Coronary Syndrome
13.6.4. Others (cardiomyopathy, etc.)
13.7. Market Attractiveness, by Indication
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals & Clinics
13.8.2. Diagnostic Laboratories
13.8.3. Homecare Settings
13.8.4. Others (Research Institutes, etc.)
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Troponin Type
13.11.2. By Setting
13.11.3. By Indication
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Cardiac Troponin Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Troponin Type, 2020-2034
14.2.1. Troponin I
14.2.2. Troponin T
14.2.3. Troponin C
14.3. Market Attractiveness, by Troponin Type
14.4. Market Value Forecast, by Setting, 2020-2034
14.4.1. Laboratory Setting
14.4.2. Point-of-Care (POC) Testing
14.5. Market Attractiveness, by Setting
14.6. Market Value Forecast, by Indication, 2020-2034
14.6.1. Myocardial Infarction
14.6.2. Congestive Heart Failure
14.6.3. Acute Coronary Syndrome
14.6.4. Others (cardiomyopathy, etc.)
14.7. Market Attractiveness, by Indication
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals & Clinics
14.8.2. Diagnostic Laboratories
14.8.3. Homecare Settings
14.8.4. Others (Research Institutes, etc.)
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Troponin Type
14.11.2. By Setting
14.11.3. By Indication
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Cardiac Troponin Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Troponin Type, 2020-2034
15.2.1. Troponin I
15.2.2. Troponin T
15.2.3. Troponin C
15.3. Market Attractiveness, by Troponin Type
15.4. Market Value Forecast, by Setting, 2020-2034
15.4.1. Laboratory Setting
15.4.2. Point-of-Care (POC) Testing
15.5. Market Attractiveness, by Setting
15.6. Market Value Forecast, by Indication, 2020-2034
15.6.1. Myocardial Infarction
15.6.2. Congestive Heart Failure
15.6.3. Acute Coronary Syndrome
15.6.4. Others (cardiomyopathy, etc.)
15.7. Market Attractiveness, by Indication
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals & Clinics
15.8.2. Diagnostic Laboratories
15.8.3. Homecare Settings
15.8.4. Others (Research Institutes, etc.)
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Troponin Type
15.11.2. By Setting
15.11.3. By Indication
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. bioMérieux SA
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Abbott Laboratories
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Siemens Healthineers India
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Eurolyser Diagnostica GmbH
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. QuidelOrtho Corporation
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Beckman Coulter, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Response Biomedical Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. LifeSign LLC
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview